Cadila Healthcare rises on USFDA nod for HIV drug

Cadila Healthcare rose 0.60% to Rs 261.75 after the company said it received final approval from the US drug regulator for Emtricitabine and Tenofovir disoproxil Fumarate tablets 200 mg/300 mg.

The company has received final approval from the US Food and Drug Administration (USFDA) to market Emtricitabine and Tenofovir Disoproxil Fumarate tablets, 200 mg/300 mg. It also received tentative approval for the strengths of 100 mg/150 mg, 133 mg/200 mg, and 167 mg/250 mg, of the same drug.

This product is used with other HIV medications to help control HIV infection. It helps to decrease the amount of HIV in the body so the immune system can work better. This will be manufactured at the group's manufacturing facility at SEZ, Ahmedabad.

The group now has 281 approvals and has so far filed over 386 abbreviated new drug applications (ANDAs) since the commencement of the filing process in FY 2003-04. The announcement was made during trading hours today, 4 March 2020.

Meanwhile, the company, on Tuesday, 3 March 2020, said it received an approval from DCGI to initiate Phase I clinical trials for its Investigational New Drug (IND) ZYBK2, a New Chemical Entity (NCE) intended to treat Rheumatoid Arthritis (RA).

On a consolidated basis, the drug maker's net profit fell 26.5% to Rs 375.18 crore on a 0.5% increase in net sales to Rs 3,534.50 crore in Q3 December 2019 Q3 December 2018.

Cadila Healthcare is a pharmaceutical company based in India.

Powered by Capital Market - Live News